PMID- 25891551
OWN - NLM
STAT- MEDLINE
DCOM- 20151015
LR  - 20151119
IS  - 2211-0356 (Electronic)
IS  - 2211-0348 (Linking)
VI  - 3
IP  - 6
DP  - 2014 Nov
TI  - Magnetic resonance imaging correlates of clinical outcomes in early multiple 
      sclerosis.
PG  - 720-7
LID - S2211-0348(14)00069-8 [pii]
LID - 10.1016/j.msard.2014.07.003 [doi]
AB  - OBJECTIVES: To study the association between changes in brain magnetic resonance 
      imaging (MRI) and clinical outcomes in early MS. METHODS: MS patients within 12 
      months of onset were enrolled and followed up to 3 years. Clinical measures 
      included Symbol Digit Modalities Test (SDMT), MS Functional Composite (MSFC) and 
      low contrast letter acuity (LCLA). MRI outcomes included brain volume changes 
      measured by SIENA and SIENAX normalized measurements [brain parenchymal volume 
      (BPV), normal-appearing white and gray matter volume (NAWMV and GMV) and T2 
      lesion volume (T2LV)]. Mixed model regression measured time trends and 
      associations between imaging and clinical outcome. RESULTS: Forty-three patients 
      were enrolled within 7.5+/-4.9 months of onset. Baseline T2 lesion volume predicted 
      subsequent changes in Paced Auditory Serial Addition Test (PASAT) (p=0.004), 
      whereas baseline measures of atrophy including BPV, GMV, and NAWMV predicted 
      longitudinal changes in MSFC (p=0.016, p=0.040, p=0.021, respectively) and 
      Timed-25 Foot Walk (p<0.05). Each 1% decrease in SIENA was associated with 1.14 
      point decrease in SDMT score (p=0.03). Each 1% decrease in brain volume SIENA was 
      associated with almost 1.5 letters decrease on LCLA (p=0.02). CONCLUSION: 
      Measures of lesion volume and overall brain volume were associated with different 
      long-term clinical outcome measures in early MS.
CI  - Copyright (c) 2014. Published by Elsevier B.V.
FAU - Maghzi, Amir-Hadi
AU  - Maghzi AH
AD  - Departments of Neurology, University of California San Francisco, San Francisco, 
      CA, United States. Electronic address: hadi.maghzi@gmail.com.
FAU - Revirajan, Nisha
AU  - Revirajan N
AD  - Departments of Neurology, University of California San Francisco, San Francisco, 
      CA, United States.
FAU - Julian, Laura J
AU  - Julian LJ
AD  - Departments of Internal Medicine, University of California San Francisco, San 
      Francisco, CA, United States.
FAU - Spain, Rebecca
AU  - Spain R
AD  - Department of Neurology, Oregon Health and Science University, OR, United States.
FAU - Mowry, Ellen M
AU  - Mowry EM
AD  - Department of Neurology, Johns Hopkins University, Baltimore, MD, United States.
FAU - Liu, Shuang
AU  - Liu S
AD  - Department of Neurology, Yale school of medicine, New Haven, CT, United States.
FAU - Jin, Chengshi
AU  - Jin C
AD  - Departments of Epidemiology and Biostatistics, University of California San 
      Francisco, San Francisco, CA, United States.
FAU - Green, Ari J
AU  - Green AJ
AD  - Departments of Neurology, University of California San Francisco, San Francisco, 
      CA, United States.
FAU - McCulloch, Charles E
AU  - McCulloch CE
AD  - Departments of Epidemiology and Biostatistics, University of California San 
      Francisco, San Francisco, CA, United States.
FAU - Pelletier, Daniel
AU  - Pelletier D
AD  - Department of Neurology, Yale school of medicine, New Haven, CT, United States.
FAU - Waubant, Emmanuelle
AU  - Waubant E
AD  - Departments of Neurology, University of California San Francisco, San Francisco, 
      CA, United States; Departments of Pediatrics, University of California San 
      Francisco, San Francisco, CA, United States.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140723
PL  - Netherlands
TA  - Mult Scler Relat Disord
JT  - Multiple sclerosis and related disorders
JID - 101580247
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Neuroprotective Agents)
RN  - 77238-31-4 (Interferon-beta)
RN  - 7LJ087RS6F (Riluzole)
RN  - XRO4566Q4R (Interferon beta-1a)
SB  - IM
MH  - Adjuvants, Immunologic/administration & dosage
MH  - Adult
MH  - Brain/drug effects/*pathology
MH  - Cross-Sectional Studies
MH  - Disability Evaluation
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Injections, Intramuscular
MH  - Interferon beta-1a
MH  - Interferon-beta/administration & dosage
MH  - Longitudinal Studies
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Multiple Sclerosis/diagnosis/drug therapy/*pathology/*physiopathology
MH  - Neuroprotective Agents/therapeutic use
MH  - Organ Size
MH  - Regression Analysis
MH  - Riluzole/therapeutic use
MH  - Severity of Illness Index
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Brain atrophy
OT  - Cognition
OT  - Magnetic resonance imaging
OT  - Multiple sclerosis
OT  - Neuroprotection
OT  - Outcomes
EDAT- 2015/04/22 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/04/21 06:00
PHST- 2014/05/29 00:00 [received]
PHST- 2014/07/12 00:00 [revised]
PHST- 2014/07/15 00:00 [accepted]
PHST- 2015/04/21 06:00 [entrez]
PHST- 2015/04/22 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S2211-0348(14)00069-8 [pii]
AID - 10.1016/j.msard.2014.07.003 [doi]
PST - ppublish
SO  - Mult Scler Relat Disord. 2014 Nov;3(6):720-7. doi: 10.1016/j.msard.2014.07.003. 
      Epub 2014 Jul 23.